The estimated Net Worth of Venture (Vi) Investments Lt... is at least $1.88 Billion dollars as of 20 April 2015. Venture Lt owns over 441,176 units of Aduro BioTech stock worth over $1,875,786,523 and over the last 10 years Venture sold ADRO stock worth over $0.
Venture has made over 1 trades of the Aduro BioTech stock since 2015, according to the Form 4 filled with the SEC. Most recently Venture bought 441,176 units of ADRO stock worth $7,499,992 on 20 April 2015.
The largest trade Venture's ever made was buying 441,176 units of Aduro BioTech stock on 20 April 2015 worth over $7,499,992. On average, Venture trades about 220,588 units every 0 days since 2015. As of 20 April 2015 Venture still owns at least 19,043,518 units of Aduro BioTech stock.
You can see the complete history of Venture Lt stock trades at the bottom of the page.
Over the last 10 years, insiders at Aduro BioTech have traded over $5,295,750 worth of Aduro BioTech stock and bought 614,134 units worth $10,440,278 . The most active insiders traders include William Mariner Greenman, Stephen T Isaacs, and Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of $2,189,064. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth $77,630.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
Aduro BioTech executives and other stock owners filed with the SEC include: